Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW. Kang MJ, et al. Among authors: kang yk. Invest New Drugs. 2012 Aug;30(4):1607-13. doi: 10.1007/s10637-011-9703-8. Epub 2011 Jun 25. Invest New Drugs. 2012. PMID: 21706149 Clinical Trial.
The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study.
Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY, Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, Lee KH, Lee SI, Cho SH, Sohn BS, Kim S, Hwang IG, Nam EM, Seo BG, Oh SC, Lee MA, Lee SC, Hong JH, Park YS. Byun JH, et al. Among authors: kang mj, kang jh, kang sy. Korean J Intern Med. 2019 Jan;34(1):165-177. doi: 10.3904/kjim.2016.348. Epub 2017 Nov 28. Korean J Intern Med. 2019. PMID: 29172407 Free PMC article.
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group.
Yoo C, Im HS, Kim KP, Oh DY, Lee KH, Chon HJ, Kim JH, Kang M, Kim I, Lee GJ, Oh SY, Choi Y, Choi HJ, Kim ST, Park JO, Ryoo BY. Yoo C, et al. Ther Adv Med Oncol. 2019 Aug 23;11:1758835919871126. doi: 10.1177/1758835919871126. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31489036 Free PMC article.
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, Kang BW, Ryu H, Lee JS, Kim KW, Abou-Alfa GK, Ryoo BY. Yoo C, et al. Among authors: kang mj, kang bw. Lancet Oncol. 2021 Nov;22(11):1560-1572. doi: 10.1016/S1470-2045(21)00486-1. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656226 Clinical Trial.
Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer.
Oh CR, Kim JE, Hong YS, Kim SY, Ahn JB, Baek JY, Lee MA, Kang MJ, Cho SH, Beom SH, Kim TW. Oh CR, et al. Among authors: kang mj. Int J Cancer. 2022 Jun 15;150(12):2038-2045. doi: 10.1002/ijc.33966. Epub 2022 Mar 1. Int J Cancer. 2022. PMID: 35179785 Clinical Trial.
Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study.
Kim JH, Cha Y, Shin SJ, Park YS, Kang JH, Kim C, Lim SH, Kang MJ, Kim JG, Hwang IG, Choi JK, Shin SH, Kang SY, Lee SC, Lim ST, Kim JS, Jeung HC, Kang MH, Choi IS, Ryu HW, Lee KH, Lee MH, Lee JY, Park JH, Jeon SY, Lee N, Park CY, Kim YH. Kim JH, et al. Among authors: kang mj, kang jh, kang mh, kang sy. Anticancer Res. 2024 Jan;44(1):347-359. doi: 10.21873/anticanres.16818. Anticancer Res. 2024. PMID: 38160001
1,491 results